Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction
Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. Journal Of The American College Of Cardiology 2003, 42: 201-208. PMID: 12875751, DOI: 10.1016/s0735-1097(03)00572-2.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAnalysis of VarianceAngiotensin-Converting Enzyme InhibitorsAspirinCase-Control StudiesCohort StudiesDrug Therapy, CombinationDrug UtilizationFemaleHumansKidney Failure, ChronicLogistic ModelsMaleMyocardial InfarctionPatient SelectionPeritoneal DialysisPlatelet Aggregation InhibitorsPractice Patterns, Physicians'PrognosisRenal DialysisRisk FactorsSurvival AnalysisTreatment OutcomeUnited StatesConceptsEnd-stage renal diseaseNon-ESRD patientsAcute myocardial infarctionESRD patientsRenal diseaseMyocardial infarctionAngiotensin-converting enzyme inhibitor therapyEnd-stage renal disease patientsAngiotensin-converting enzyme inhibitorStandard medical therapyEnzyme inhibitor therapyRenal disease patientsCooperative Cardiovascular Project databaseHigh-risk populationLogistic regression modelsEarly administrationInhibitor therapyMedical therapyACE inhibitorsAMI patientsPeritoneal dialysisPoor prognosisDisease patientsESRD databasePatients